Question · Q4 2025
Joysree Zanfir asked about the anticipated enrollment curve for KPL-387's Phase III portion after completing Phase II, and if there are differences in patient types being enrolled compared to the RHAPSODY study.
Answer
Chief Medical Officer John Paolini explained that KPL-387 is a global study enrolling patients with recurrent pericarditis, similar to RHAPSODY's design, but Arcalyst is currently only available in the U.S. He reiterated guidance for Phase II data in H2 2026 and potential drug availability in 2028-2029, with Phase III initiation guidance yet to be provided.
Ask follow-up questions
Fintool can predict 
KNSA's earnings beat/miss a week before the call